# Arid1a loss accelerates pancreatic ductal adenocarcinoma precursor formation

> **NIH NIH K08** · UT SOUTHWESTERN MEDICAL CENTER · 2022 · $160,920

## Abstract

PROJECT SUMMARY/ABSTRACT
Pancreatic ductal adenocarcinoma (PDAC) patients have an expected 5-year survival of less than 10% in large
part to the lack of effective therapeutics. Detailed understanding of the molecular mechanisms that drive
pancreas cancer formation and progression are desperately needed to develop new therapies for this intractable
disease. ARID1A, which is part of the SWI/SNF chromatin remodeling complex, is one of the most commonly
mutated genes in PDAC but the effects of the mutation are unknown. We found that Arid1a deletion in mouse
leads to accelerated formation of pancreatic intraepithelial neoplasms (PanIN), which are precursors to PDAC.
We also found that protein synthesis is aberrantly elevated after Arid1a loss, which suggests that protein
translation may be a therapeutic target. The overall objective of this study is to determine how ARID1A deletion
in acinar cells accelerates the formation PanIN by determining 1) if Arid1a mutations accelerate not only the
formation of PanIN but also their progression to PDAC, 2) the epigenetic effects of Arid1a deletion in the
pancreas, and 3) if blocking protein synthesis can prevent Arid1a induced PanIN formation. At the completion of
our proposal, we expect that we will better understand how ARID1A and chromatin remodeling affect pancreas
cancer initiation and progression and potentially identify new therapeutic targets.
The proposed project will be part of my continued training and development to become an independent
investigator. The training plan includes coursework, hands-on experience, and closed mentorship from a team
of experienced and accomplished scientists. Dr. Hao Zhu will be my co-mentor. He is an expert in the role of
SWI/SNF in liver regeneration and cancer. Dr. Rolf Brekken, an expert in tumor microenvironment and
angiogenesis and has extensive experience studying pancreas cancer in mice, will be my co-mentor. My
scientific advisory team includes 1) Dr. Sean Morrison, a Howard Hughes Investigator and an expert in
hematopoietic stem cell biology, including protein synthesis, 2) Dr. Jian Xu, an expert in epigenetics and protein
synthesis 3) Dr. Joshua Mendell, a Howard Hughes Investigator and an expert in post-transcription gene
regulation. They will provide guidance for my science, mentorship for career development, and technical support.
The Department of Surgery has committed to protecting 80% of my time for research endeavors, fully supporting
my salary, and maintaining these arrangements regardless of the outcome of this award application.
The Zhu lab is based in the Children’s Research Institute, which is headed by Dr. Morrison. It is a multidisciplinary
institute that focuses on stem cell biology, cancer, and metabolism. It is an incredibly collaborative and well-
resourced environment and is an outstanding training environment.

## Key facts

- **NIH application ID:** 10438684
- **Project number:** 5K08CA222611-05
- **Recipient organization:** UT SOUTHWESTERN MEDICAL CENTER
- **Principal Investigator:** Sam C. Wang
- **Activity code:** K08 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $160,920
- **Award type:** 5
- **Project period:** 2018-07-15 → 2023-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10438684

## Citation

> US National Institutes of Health, RePORTER application 10438684, Arid1a loss accelerates pancreatic ductal adenocarcinoma precursor formation (5K08CA222611-05). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10438684. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*